Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial.

Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, Tanaka M. · 2022

Read Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. by Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, Tanaka M. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9388376.txt.

Introduction

Todo and co-authors report a phase 2 trial of a cancer-killing herpes virus for stubborn glioblastoma. The virus, G47-delta, carries three mutations that aim it at tumor cells. Nineteen adults with leftover or returned tumors got up to six injections into the tumor. All had prior radiation and temozolomide therapy.

One-year survival after treatment start was 84.2%, with 16 of 19 patients alive. That beat the preset target, and the trial stopped early. Median survival reached 20.2 months from treatment and 28.8 months from first surgery. Fever was the most common side effect, in 17 of 19 patients. Scans showed a repeating pattern of swelling then clearing inside the lesion. Biopsies found rising immune cell entry into tumors. The results led to approval in Japan, a first for such a product.

Catalog record

CREATORTodo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, Tanaka M.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE69 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9388376

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial By Tomoki Todo, Hirotaka Ito, Yasushi Ino, Hiroshi Ohtsu, Yasunori Ota, Junji Shibahara, Minoru Tanaka Published in: Nature Medicine DOI: 10.1038/s41591-022-01897-x ABSTRACT This investigator-initiated, phase 2, single-arm trial primarily assessed the efficacy of G47∆, a triple-mutated, third-generation oncolytic herpes simplex virus type 1, in 19 adult patients with residual or recurrent, supratentorial glioblastoma after radiation therapy and temozolomide (UMIN-CTR Clinical Trial Registry UMIN000015995). G47Δ was administered intratumorally and repeatedly for up to six doses. The primary endpoint of 1-yr survival rate after G47∆ initiation was 84.2% (95% confidence interval, 60.4–96.6; 16 of 19). The prespecified endpoint was met and the trial was terminated early. Regarding secondary endpoints, the median overall survival was 20.2 (16.8–23.6) months after G47∆ initiation and 28.8 (20.1–37.5) months from the initial surgery. The most common G47∆-related adverse event was fever (17 of 19) followed by vomiting, nausea, lymphocytopenia and leukopenia. On magnetic resonance imaging, enlargement of and contrast-enhancement clearing within the target lesion repeatedly occurred after each G47∆ administration, which was characteristic to this therapy. Thus, the best overall response in 2 yr was partial response in one patient and stable disease in 18 patients. Biopsies revealed increasing numbers of tumor-infiltrating CD4+/CD8+ lymphocytes and persistent low numbers of Foxp3+ cells. This study showed a survival benefit and good safety profile, which led to the approval of G47∆ as the first oncolytic virus product in Japan. MAIN Glioblastoma has a poor prognosis with a median overall survival (OS) of 20.9 months despite the current Stupp regimen of radiotherapy plus temozolomide together with tumor-treating fields (TTF)1. This regimen with TTF is the current standard-of-care for newly diagnosed glioblastoma in the United States, but its recommendation level as a standard-of-care varies among countries outside the United States. None of the current therapies can yet prevent recurrence of glioblastoma, not to mention cure it, so nonconventional therapeutic approaches are needed especially for recurrent cases. G47Δ is a triple-mutated, third-generation oncolytic herpes simplex virus type 1 (HSV-1) constructed by deleting the α47 gene and overlapping US11 promoter from parental G207, a second-generation oncolytic HSV-1 with deletions in both copies of the γ34.5 gene and an inactivation of the ICP6 gene2. G47Δ shows greater tumor-specific replication capability and cytopathic effects than G207 but retains a high safety profile3,4. G47Δ was confirmed safe in the first-in-human (FIH) trial when administered intratumorally, two doses within 2 weeks, to patients with recurrent glioblastoma5. Preclinical studies show that G47∆ exhibits efficacy via two mechanisms: (1) an immediate effect via virus replication and direct oncolytic activity; and (2) a delayed effect via induction of specific antitumor immunity2. In Japan, national health insurance allows patients to choose any government-approved treatment at any institution and at relatively low cost6. In clinical studies for lethal diseases in Japan, setting a noncurable standard-care control arm would not be accepted and also would be unethical, especially if the study was an academia-initiated, research grant-supported drug development such as this. Further, because G47∆ needs to be administered by surgery, blinding treatment arms and allowing sham surgery on randomly selected patients would not be considered acceptable in Japan. This phase 2 trial is, therefore, designed as a single-arm trial to evaluate the efficacy of G47Δ in patients with glioblastoma that was residual or recurred after initial therapy of surgery, radiation and temozolomide. RESULTS The interim analysis in 13 patients showed a 1-yr survival rate after G47∆ initiation of 92.3% (95% confidence interval (95% CI), 64.0–99.8). Compared with the preset control value of 15%, the O’Brien–Fleming boundary was crossed for the planned interim report (Z0 = 7.806). This confirmed that the prespecified primary endpoint of this study was met and, therefore, the trial was terminated early by the recommendation of the Independent Data Monitoring Committee and as predetermined by the protocol. Of 28 patients who gave informed consent, 19 patients who matched the eligibility criteria had been enrolled and composed the full analysis set (FAS) (Extended Data Fig. 1). Demographics and baseline clinical characteristics of these 19 enrolled patients are shown in Table 1.Table 1Baseline demographic and clinical characteristicsPt no.Sex/ ageKPSTumor locationSurgeryRadiation (Gy/fr)Chemotherapy other than TMZHSV-1 IgM/IgGaKi-67 (%)IDH1MGMT promoter MSPMGMT expressionRec/ ResTime from initial surgery to G47Δ (months)Tumor area Baseline (mm2)MET-PET L/NSteroidsBefore G47ΔNew or increased dose during G47Δ treatment1M/5490R/FrGTR50.4/28−0.23/<2.04wtNA+1st12.4375.21.71−−2M/4990R/FrPR60/30−0.09/<2.05wtNA−Res3.0220.01.50−−3F/6380L/FrPR60/30−0.10/15.15wtNA+Res3.4661.43.62−−4M/6990L/TGTR60/30−0.19/2.715wtunmet+1st8.7176.91.78−−5M/46100R/FrGTR50.4/28BEV0.46/51.46wtunmet−1st14.1554.21.95−Hydrocortisone (500 mg ×1 dose, 5 times)6F/2570L/PPR60/30BEV, BCNU wafer0.13/<2.07mtunmet+2nd23.5696.62.15−−7M/5190R/TPR60/30−0.44/<2.040wtNA−Res3.0440.72.50−−8M/7370R/FrPR60/30−0.18/123.030wtNA+1st5.31,386.51.02Prednisolone 10 mg d−1−9M/46100R/FrGTR60/30BCNU wafer, IFNβ0.18/<2.08wtNA−1st24.9122.41b−−10M/28100L/FrGTR60/30BEV, BCNU wafer0.24/<2.030–40mtNA−1st9.4141.41.60−−11M/5380R/TGTR60/30BCNU wafer0.20/<2.02mtNA−1st7.4416.21.35−−12M/5970L/FrBiopsy60/30BEV0.31/2.340wtmet−1st4.2519.91.38−Dexamethasone (19.8 mg d−1 to 6.6 mg d−1 ×6 d, 1 time)13F/5370R/FrPR60/30BEV, BCNU wafer0.45/105.030mtmet−Res4.1873.11.86−−14M/4280SpleniumPR60/30−0.19/<2.050wtNA+1st10.11,832.22.27−Dexamethasone (19.8 mg d−1 to 13.2 mg d−1 ×4 d, 1 time); prednisolone (30 mg d−1 to 15 mg d−1 ×6 d, 1 time)15M/6580L/PBiopsy60/30BEV0.23/164.015wtNA+Res4.4652.81.54−Betamethasone (24 mg d−1 to 6 mg d−1 ×6 d, 1 time)16M/45100R/FrPR60/30BCNU wafer0.10/<2.050mtNA−Res3.12,306.72.64−−17M/6890R/TPR60/30−0.18/220.020wtNA+Res3.9291.52.39−−18F/4380L/PBiopsy60/30BEV0.30/216.010wtNA−Res3.8513.52.01−Prednisolone (30 mg d−1 ×7 d, 1 time)19M/3580R/FrPR59.4/33−0.14/<2.090mtNA−Res3.6778.51.27−−Abbreviations: F, female; M, male; KPS, Karnofsky Performance Scale; R, right; L, left; Fr, frontal lobe; T, temporal lobe; P, parietal lobe; GTR, gross total resection; PR, partial resection; TMZ, temozolomide; BEV, bevacizumab; BCNU wafer, carmustine wafer; IFNβ, interferon-β; HSV-1, herpes simplex virus type 1; IDH1, isocitrate dehydrogenase 1; mt, mutant type; wt, wild type; MGMT, methylguanine methyltransferase; MSP, methylation-specific PCR; met, methylated; unmet, unmethylated; NA, not available; Rec, recurrent; Res, residual; 1st, first recurrence; 2nd, second recurrence; MET, methionine; PET, positron emission tomography; L/N, lesion-to-normal ratio.a1 d before first therapy.bL/N could not be measured, because there was no increased uptake corresponding to the target lesion.GTR is defined as >95% of the tumor removed assessed by the surgeon. Resection other than GTR is either PR or biopsy as judged by the surgeon.Immunohistochemistry for MGMT expression: –, <10%; +, ≥10% and <50%; ++, ≥50%. Magnetic resonance imaging (MRI)-guided stereotactic injection A total of 97 stereotactic surgeries were performed in 19 enrolled patients. Twelve patients (63.2%) received G47Δ administration the maximum of six times (Table 2). For the others, G47∆ treatment was discontinued for meeting one of the treatment discontinuation criteria, as follows: progressive disease judgment by increase in target lesion size (n = 3), aggravation of symptoms (n = 2), clinical judgment by investigator (postoperative infection) (n = 1) and shrinkage of the target lesion to <1 cm in diameter (n = 1).Table 2Summary of patient outcomesPatient no.Sex/ ageNumber of G47∆ dosesTime to progression (d)aBest responseOS (d)Treatment after progressionOutcomeAutopsyCause of deathAfter initial surgeryAfter 1st G47Δ therapy1M/546258SD863485Bevacizumab after reoperation (GTR)Dead+Tumor progression2M/496588SD1,7481,657Extended field SRSDead+Tumor progression3F/636762bSD1,044941−Dead−Tumor progression4M/695115SD891626BevacizumabDead−Tumor progression5M/466133SD1,310882Bevacizumab after reoperation (GTR) NimustineDead+Tumor progression6F/25343SD897181BevacizumabDead−Tumor progression7M/51264SD489398BevacizumabDead−Tumor progression8M/736294SD817655Extended field SRS; bevacizumabDead−Tumor progression9M/4661,696bSD2,716c1,960c−StableNANA10M/28479SD1,4521,166Extended field SRSDead−Tumor progression11M/5361,584bSD2,073c1,848c−StableNANA12M/596139SD596469BevacizumabDead−Tumor progression13F/536573bSD709583−Dead+Not related to the disease14M/42478SD543236BevacizumabDead−Tumor progression15M/656142SD569434BevacizumabDead−Tumor progression16M/456163SD699606Extended field SRS; bevacizumabDead+Tumor progression17M/682127PR1,554c1,435cBevacizumab after reoperation (partial resection)StableNANA18F/435108SD244127−Dead−Tumor progression19M/356331SD667556Bevacizumab; spinal irradiationDead−Tumor progressionAbbreviations: F, female; M, male; PR, partial response; SD, stable disease; GTR, gross total resection; SRS, stereotactic radiosurgery (radiotherapy).aIncluding the date of first administration.bTumor progression occurred after initial cut-off date for judgment of outcome.cPatient remained alive at most recent observation date (1 March 2022) used to analyze survival.Extent of tumor resection at reoperation: GTR is defined as >95% of the tumor removed assessed by the surgeon. Efficacy The primary endpoint was the 1-yr survival rate and the secondary endpoints included OS and progression-free survival (PFS), all after G47∆ initiation. For the FAS population, the 1-yr survival rate after G47∆ initiation was 84.2% (95% CI, 60.4–96.6). The median OS was 20.2 (16.8–23.6) months after G47∆ initiation (Fig.

Read the complete text